Asthenic syndrome in context of COVID-19 pandemic
https://doi.org/10.33667/2078-5631-2020-33-26-34
Abstract
The article is devoted to the current problems of fatigue during the new coronavirus infection pandemic. The pathogenetic mechanisms of fatigue in the acute period of infection are considered, as well as potential mechanisms and factors influencing post-viral fatigue development after COVID-19 infection. A biopsychosocial approach to the pathogenesis and treatment of post-viral fatigue is proposed. In conclusion, the factors contributing to quarantine fatigue development and methods of its therapy are considered.
About the Authors
Yu. D. Vorobyova
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Moscow
Russian Federation
Moscow
G. M. Diukova
I. M. Sechenov First Moscow State Medical University (Sechenov University); A. S. Loginov Moscow Clinical Scientific Center
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Kazuhiro K. Post-Infectious Fatigue. JMAJ. 49 (1): 27–33, 2006.
2. Diukova G. M. Asthenic syndrome: problems of diagnostics and treatment. Effective pharmacotherapy. Neurology and psychiatry. 2012. № 1. S. 16–22 (in Russian).
3. Borsook D, Youssef AM, Simons L, Elman I, Eccleston C. When pain gets stuck: the evolution of pain chronification and treatment resistance. Pain. 2018; 159 (12): 2421–2436. DOI: 10.1097/j.pain.0000000000001401.
4. Intel from an outpatient COVID-19 clinic Harvard health https://news.harvard.edu/gazette/story/2020/05/why-it-is-critical-to-distinguish-covid-19-from-otherinfections/
5. Временные методические рекомендации МЗ ФР Версия 6 (26.04.2020) «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)».
6. Clinical care guidelines. Centers for disease control and prevention. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
7. Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and Epidemiological Characteristics of 1,420 European Patients with mild-to-moderate Coronavirus Disease 2019 [published online ahead of print, 2020 Apr 30]. J Intern Med. 2020; 10.1111/joim.13089. DOI: 10.1111/joim.13089.
8. Abbas H. Panju, David Kelvin, Mark D. Minden, Shabbir M. H. Alibhai; Relationship between Fatigue and Cytokine Levels in Patients Age 50+ with Acute Myeloid Leukemia (AML). Blood 2006; 108 (11): 4507. DOI: https://doi.org/10.1182/blood.V108.11.4507.4507
9. Bower JE. Cancer-related fatigue–mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014; 11 (10): 597–609. DOI: 10.1038/nrclinonc.2014.127.
10. Zielinski MR, Systrom DM, Rose NR. Fatigue, Sleep, and Autoimmune and Related Disorders. Front Immunol. 2019; 10: 1827. Published 2019 Aug 6. DOI: 10.3389/fimmu.2019.01827/
11. Yamato M, Kataoka Y. Fatigue sensation following peripheral viral infection is triggered by neuroinflammation: who will answer these questions? Neural Regen Res. 2015; 10 (2): 203–204. DOI: 10.4103/1673–5374.152369.
12. Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007; 45 (2): 27–37. DOI: 10.1097/AIA.0b013e318034194e.
13. Neri S, Pistone G, Saraceno B, Pennisi G, Luca S, Malaguarnera M. L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. Neuropsychobiology. 2003; 35: 94–97.
14. Katafuchi T, Kondo T, Take S, Yoshimura M. Enhanced expression of brain interferon-alpha and serotonin transporter in immunologically induced fatigue in rats. Eur J Neurosci. 2005; 22 (11): 2817–2826. DOI: 10.1111/j.1460–9568.2005.04478.x.
15. Archer MI. The post-viral syndrome: a review. J R Coll Gen Pract. 1987; 37 (298): 212–214.
16. Rasa S, Nora-Krukle Z, Henning N, et al. Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med. 2018; 16 (1): 268. Published 2018 Oct 1. DOI: 10.1186/s12967–018–1644-y.
17. Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011; 11: 37. Published 2011 Mar 24. DOI: 10.1186/1471–2377–11–37.
18. Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev. 2009; 8 (4): 287–291. DOI: 10.1016/j.autrev.2008.08.003.
19. Filler K, Lyon D, Bennett J, et al. Association of Mitochondrial Dysfunction and Fatigue: A Review of the Literature. BBA Clin. 2014; 1: 12–23. DOI: 10.1016/j.bbacli.2014.04.001.
20. Smits B., van den Heuvel L., Knoop H., Kusters B., Janssen A., Borm G., van Engelen B. Mitochondrial enzymes discriminate between mitochondrial disorders and chronic fatigue syndrome. Mitochondrion. 2011; 11 (5): 735–738.
21. Booth N. E., Myhill S., McLaren-Howard J. Mitochondrial dysfunction and the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/ CFS) Int. J. Clin. Exp. Med. 2012; 5 (3) 208–220.
22. Cope H, Mann A, Pelosi A, David A. Psychosocial risk factors for chronic fatigue and chronic fatigue syndrome following presumed viral illness: a case-control study. Psychol Med. 1996; 26 (6): 1197–1209. DOI: 10.1017/s0033291700035923.
23. Chen R, Liang FX, Moriya J, et al. Chronic fatigue syndrome and the central nervous system. J Int Med Res. 2008; 36 (5): 867–874. DOI: 10.1177/147323000803600501.
24. Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006; 333 (7568): 575. DOI: 10.1136/bmj.38933.585764.AE.
25. Lim, E., Ahn, Y., Jang, E. et al. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Transl Med 18, 100 (2020). https://doi.org/10.1186/s12967–020–02269–0
26. Price JR, Mitchell E, Tidy E, Hunot V. Cognitive behaviour therapy for chronic fatigue syndrome in adults. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD 001027. DOI: 10.1002/14651858.CD001027.pub2.
27. Salamone JD, Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron. 2012; 76 (3): 470–485. DOI: 10.1016/j.neuron.2012.10.021
28. P. O. Behan, B.A.G. Haniffah, D. P. Doogan, M. Loudon, A Pilot Study of Sertraline for the Treatment of Chronic Fatigue Syndrome, Clinical Infectious Diseases, Volume 18, Issue Supplement_1, January 1994, Page S 111, https://doi.org/10.1093/clinids/18.Supplement_1.S111
29. Ronfeld R. A., Tremaine L. M., Wilner K. D. Pharmacokinetics of sertralin and N-demethyl metabolite in elderly and young male and female volunteers. Clin. Pharmacokinet. 1997. Vol. 32. Suppl. 1. P. 22–30.
30. Maric D, Brkic S, Tomic S, Novakov Mikic A, Cebovic T, Turkulov V. Multivitamin mineral supplementation in patients with chronic fatigue syndrome. Med Sci Monit. 2014; 20: 47–53. Published 2014 Jan 14. DOI: 10.12659/MSM.889333
31. Earl KE, Sakellariou GK, Sinclair M, et al. Vitamin D status in chronic fatigue syndrome/myalgic encephalomyelitis: a cohort study from the North-West of England. BMJ Open. 2017; 7 (11): e015296. Published 2017 Nov 8. DOI: 10.1136/bmjopen-2016–015296.
32. Plescheva A, Pigarova E Dzeranova L. Changes in anxiety and depression symptoms in patients with chronic fatigue syndrome treated with vitamin D. Endocrine Abstracts.2013; 32: 119 Effect of vitamin D 3 on self-perceived fatigue A double-blind randomized placebo-controlled trial.
33. Nowak A, Boesch L, Andres E, et al. Effect of vitamin D 3 on self-perceived fatigue: A double-blind randomized placebo-controlled trial [published correction appears in Medicine (Baltimore). 2017 Jan 20; 96 (3): e6038]. Medicine (Baltimore). 2016; 95 (52): e5353. DOI: 10.1097/MD.0000000000005353.
34. Vanherwegen AS, Gysemans C, Mathieu C. Regulation of Immune Function by Vitamin D and Its Use in Diseases of Immunity. Endocrinol Metab Clin North Am. 2017; 46 (4): 1061–1094. DOI: 10.1016/j.ecl.2017.07.010.
35. Jayedi A, Rashidy-Pour A, Shab-Bidar S. Vitamin D status and risk of dementia and Alzheimer's disease: A meta-analysis of dose-response †. Nutr Neurosci. 2019; 22 (11): 750–759. DOI: 10.1080/1028415X.2018.1436639.
36. Kuznetzov I. A., Smirnov A. M., Kuraleva O. O., Bistryakova E. A., Laleikina I. A., Begmetove M. H. Biological and pharmacological properties of Trekresan. Modern problems of science and educarion. 2015, № 1–1 (in Russian).
37. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, Rubin GJ. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet 2020; 395 (10227): 912–20 DOI: https://doi.org/10.1016/S0140–6736(20)30460–8/.
Review
For citations:
Vorobyova Yu.D., Diukova G.M. Asthenic syndrome in context of COVID-19 pandemic. Medical alphabet. 2020;(33):26-34. (In Russ.) https://doi.org/10.33667/2078-5631-2020-33-26-34
Views:
1920
Email this article 